{
  "docId": "019de073-bfd4-723b-805d-c3152d3a00ff",
  "docSlug": "7df1d9bdbc08777b7243fabbc766ed39",
  "documentTitle": "Immatics | Results Presentation Deck | 25 slides",
  "authorId": "immatics",
  "authorName": "Immatics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7860465,
  "pageNumber": 4,
  "pageCount": 25,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a process flow diagram to show the progression of clinical trial cohorts.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-bfd4-723b-805d-c3152d3a00ff/4",
  "deckHref": "/decks/019de073-bfd4-723b-805d-c3152d3a00ff",
  "deckJsonHref": "/decks/019de073-bfd4-723b-805d-c3152d3a00ff.json",
  "deckAnchorHref": "/decks/019de073-bfd4-723b-805d-c3152d3a00ff#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.6,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Flow from Phase 1a to Phase 1b cohorts A, B, and C",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "98fb1b7d-c4ea-4b94-9b4e-30a484498b94",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.22,
        "x": 0.75,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "Each expansion cohort is designed to establish safety, evaluate the observed objective response rate, demonstrate durability & provide the trigger for registration trials",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0901841-3f23-49eb-bab5-77be95915266",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.98,
        "x": 0.01,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "RP2D (target dose) determined at DL4, exploration of higher dose (DL5) ongoing; Demonstrated to be associated with durable response: Locke et al. 2020 Blood Advances; Opdivo (nivolumab): programmed death-1 (PD-1) immune checkpoint inhibitor; Treatment of n=3 patients in DL3 prior to patient treatment at provisional RP2D (DL4); Demonstrated to be important for long-term remission: Melenhorst et al. 2022 Nature, Bai et al. 2022 Science Advances",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90bac458-5673-44df-98b3-668fa3e18854",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.65,
        "x": 0.03,
        "y": 0.11
      },
      "kind": "title",
      "text": "Three Phase 1b Expansion Cohorts to Establish Durable Objective Responses",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "290a1e3f-ab54-4e6a-8403-e6f716cb9403",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.35,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "IMA203 TCR-T Phase 1 Design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f27ab1cd-698c-4403-9df0-2a90d0419e51",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "1cedd8a9-d42b-4ff6-9163-d8e44058ece6",
      "evidence": "The slide uses a flow diagram to show the progression of clinical trial stages.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 5,
      "from": 1,
      "beatId": "39977078-411b-45f2-92d7-41e13bcde396",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "Slides 1-5 introduce the therapy and the need for effective cancer treatments.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}